Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Kane Biotech Inc
V.KNE
Alternate Symbol(s):
KNBIF
Healthcare
Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired...
from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:KNE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(202)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 26, 2024 6:10am
RE:June 25th - insider transaction
Good to see but at the same time that make me wonder if we'll have a news about Revyve production. Usually insiders are in a blackout before any material news...
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Jun 25, 2024 10:37pm
June 25th - insider transaction
Interesting...see link below...an insider bought a 'few' shares today; Mr. Edwards shares purchase GLTA
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 25, 2024 10:32pm
RE:RE:RE:Latest DispersinB news from this week (and last)
Yup, I need to dig a little more but I think that DispersinB is already considered safe and I-Med will only add it to their product lines and get the FDA to approve the new formula. KNE is trying to
...more
(202)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 25, 2024 4:19pm
RE:RE:Latest DispersinB news from this week (and last)
Someone on CEO answered the same question and it make sense https://ceo.ca/kne?fa89a80c871f
(202)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 25, 2024 12:22pm
RE:Latest DispersinB news from this week (and last)
How can they have a deal for something that is not approved and will most likely take several years to have approval ?
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Jun 25, 2024 9:53am
Latest DispersinB news from this week (and last)
Surprising licensing deal for DispersinB was announced earlier today...see link below; I-Med Pharma licensing deal announcement On a less positive note, the DispersinB phase 1 trial was postponed
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 13, 2024 12:56pm
RE:RE:RE:Apart from traveling
100% agree with your comment about KNE typically not meeting deadlines...deadlines that they are setting themself...I think that they should be using a more conservative approach when mentioning
...more
(202)
•••
RoyMax123
X
View Profile
View Bullboard History
Comment by
RoyMax123
on Jun 13, 2024 12:43pm
RE:RE:Apart from traveling
Hopefully that "before end of June" deadline will be more accurate than all others deadline they gave in the past.
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Jun 13, 2024 10:12am
RE:Apart from traveling
The next big news will be the start of the 'Revyve' commercial production (before end of June, per KNE) and product shipment to Progenacare. This should prevent them to run out of cash for a
...more
(202)
•••
RoyMax123
X
View Profile
View Bullboard History
Post by
RoyMax123
on Jun 13, 2024 10:04am
Apart from traveling
it seems that nothing happen, still no production, no acne trial etc... I won't be surprise if they run out of cash before anything serious happen.
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on May 24, 2024 10:14am
RE:New Press Release - Kane Biotech Announces First Quarter 2024 Financial Results
Interesting to see that STEM Animal sales was picking up in Q1...that explain why they got a good offer from Dechra. The AGM meeting was interesting in a way that they confirmed everything that was
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 23, 2024 4:15pm
New Press Release - Kane Biotech Announces First Quarter 2024 Financial Results
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The Company previously announced on April 11, 2024 that it had reached an agreement in principle for the...
read article.
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on May 17, 2024 1:25pm
Technically speaking (update)
As mentioned before, technical analysis for a microcap company is not as good as for larger companies but, it is interesting to note the following about KNE; 1. Short Term: The daily graph is in
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 16, 2024 8:00am
New Press Release - Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income